159 related articles for article (PubMed ID: 19797880)
1. [Examination of questionnaires regarding diabetic peripheral neuropathy in epalrestat-treated patients and their usefulness in the treatment of the patients during the treatment course].
Ito A; Ishii-Nozawa R; Ibuki C; Atarashi H; Kataoka H; Takeuchi K
Yakugaku Zasshi; 2009 Oct; 129(10):1239-47. PubMed ID: 19797880
[TBL] [Abstract][Full Text] [Related]
2. Effects of epalrestat, an aldose reductase inhibitor, on diabetic peripheral neuropathy in patients with type 2 diabetes, in relation to suppression of N(ɛ)-carboxymethyl lysine.
Kawai T; Takei I; Tokui M; Funae O; Miyamoto K; Tabata M; Hirata T; Saruta T; Shimada A; Itoh H
J Diabetes Complications; 2010; 24(6):424-32. PubMed ID: 19716319
[TBL] [Abstract][Full Text] [Related]
3. I-123 MIBG cardiac imaging in diabetic neuropathy before and after epalrestat therapy.
Utsunomiya K; Narabayashi I; Nakatani Y; Tamura K; Onishi S
Clin Nucl Med; 1999 Jun; 24(6):418-20. PubMed ID: 10361937
[TBL] [Abstract][Full Text] [Related]
4. Aldose reductase inhibition ameliorates pupillary light reflex and F-wave latency in patients with mild diabetic neuropathy.
Nakayama M; Nakamura J; Hamada Y; Chaya S; Mizubayashi R; Yasuda Y; Kamiya H; Koh N; Hotta N
Diabetes Care; 2001 Jun; 24(6):1093-8. PubMed ID: 11375376
[TBL] [Abstract][Full Text] [Related]
5. Erythrocyte sorbitol level as a predictor of the efficacy of epalrestat treatment for diabetic peripheral polyneuropathy.
Ando H; Takamura T; Nagai Y; Kaneko S;
J Diabetes Complications; 2006; 20(6):367-70. PubMed ID: 17070440
[TBL] [Abstract][Full Text] [Related]
6. Long-term clinical effects of epalrestat, an aldose reductase inhibitor, on diabetic peripheral neuropathy: the 3-year, multicenter, comparative Aldose Reductase Inhibitor-Diabetes Complications Trial.
Hotta N; Akanuma Y; Kawamori R; Matsuoka K; Oka Y; Shichiri M; Toyota T; Nakashima M; Yoshimura I; Sakamoto N; Shigeta Y
Diabetes Care; 2006 Jul; 29(7):1538-44. PubMed ID: 16801576
[TBL] [Abstract][Full Text] [Related]
7. Effects of epalrestat, an aldose reductase inhibitor, on diabetic neuropathy and gastroparesis.
Okamoto H; Nomura M; Nakaya Y; Uehara K; Saito K; Kimura M; Chikamori K; Ito S
Intern Med; 2003 Aug; 42(8):655-64. PubMed ID: 12924487
[TBL] [Abstract][Full Text] [Related]
8. Epalrestat: an aldose reductase inhibitor for the treatment of diabetic neuropathy.
Ramirez MA; Borja NL
Pharmacotherapy; 2008 May; 28(5):646-55. PubMed ID: 18447661
[TBL] [Abstract][Full Text] [Related]
9. Effect of 24 weeks of treatment with epalrestat, an aldose reductase inhibitor, on peripheral neuropathy in patients with non-insulin-dependent diabetes mellitus.
Uchida K; Kigoshi T; Nakano S; Ishii T; Kitazawa M; Morimoto S
Clin Ther; 1995; 17(3):460-6. PubMed ID: 7585850
[TBL] [Abstract][Full Text] [Related]
10. Cardiac sympathetic neuropathy and effects of aldose reductase inhibitor in streptozotocin-induced diabetic rats.
Kurata C; Okayama K; Wakabayashi Y; Shouda S; Mikami T; Tawarahara K; Sugiyama T
J Nucl Med; 1997 Nov; 38(11):1677-80. PubMed ID: 9374332
[TBL] [Abstract][Full Text] [Related]
11. [Effects of the aldose reductase inhibitor on diabetic polyneuropathy--the efficacy of F wave measurement].
Shimada H; Miki T; Kyogoku I; Kawagishi T; Inaba M; Okuno Y; Nishizawa Y; Morii H
No To Shinkei; 1998 Sep; 50(9):817-20. PubMed ID: 9789304
[TBL] [Abstract][Full Text] [Related]
12. Long-term clinical effects of epalrestat, an aldose reductase inhibitor, on progression of diabetic neuropathy and other microvascular complications: multivariate epidemiological analysis based on patient background factors and severity of diabetic neuropathy.
Hotta N; Kawamori R; Fukuda M; Shigeta Y;
Diabet Med; 2012 Dec; 29(12):1529-33. PubMed ID: 22507139
[TBL] [Abstract][Full Text] [Related]
13. Clinical investigation of epalrestat, an aldose reductase inhibitor, on diabetic neuropathy in Japan: multicenter study. Diabetic Neuropathy Study Group in Japan.
Hotta N; Sakamoto N; Shigeta Y; Kikkawa R; Goto Y
J Diabetes Complications; 1996; 10(3):168-72. PubMed ID: 8807467
[TBL] [Abstract][Full Text] [Related]
14. Repurposing the aldose reductase inhibitor and diabetic neuropathy drug epalrestat for the congenital disorder of glycosylation PMM2-CDG.
Iyer S; Sam FS; DiPrimio N; Preston G; Verheijen J; Murthy K; Parton Z; Tsang H; Lao J; Morava E; Perlstein EO
Dis Model Mech; 2019 Nov; 12(11):. PubMed ID: 31636082
[TBL] [Abstract][Full Text] [Related]
15. Effect of aldose reductase inhibitor ONO 2235 on reduced sympathetic nervous system activity and peripheral nerve disorders in STZ-induced diabetic rats.
Yoshida T; Nishioka H; Yoshioka K; Nakano K; Kondo M; Terashima H
Diabetes; 1987 Jan; 36(1):6-13. PubMed ID: 3025043
[TBL] [Abstract][Full Text] [Related]
16. Effects of aldose reductase inhibitor on microneurographically assessed peripheral sympathetic nerve activity in rats.
Sato D; Kusunoki M; Shinzawa G; Feng Z; Nishina A; Nakamura T
Auton Neurosci; 2015 Dec; 193():69-73. PubMed ID: 26272532
[TBL] [Abstract][Full Text] [Related]
17. Long-term effect of epalrestat on cardiac autonomic neuropathy in subjects with non-insulin dependent diabetes mellitus.
Ikeda T; Iwata K; Tanaka Y
Diabetes Res Clin Pract; 1999 Mar; 43(3):193-8. PubMed ID: 10369429
[TBL] [Abstract][Full Text] [Related]
18. A placebo-controlled double-blind study of epalrestat (ONO-2235) in patients with diabetic neuropathy.
Goto Y; Hotta N; Shigeta Y; Sakamoto N; Kito S; Matsuoka K; Takahashi A; Kikkawa R; Sakuma A
Diabet Med; 1993; 10 Suppl 2():39S-43S. PubMed ID: 8334840
[No Abstract] [Full Text] [Related]
19. The aldose reductase inhibitor epalrestat exerts nephritic protection on diabetic nephropathy in db/db mice through metabolic modulation.
He J; Gao HX; Yang N; Zhu XD; Sun RB; Xie Y; Zeng CH; Zhang JW; Wang JK; Ding F; Aa JY; Wang GJ
Acta Pharmacol Sin; 2019 Jan; 40(1):86-97. PubMed ID: 29930278
[TBL] [Abstract][Full Text] [Related]
20. Effect of aldose reductase inhibitor on cutaneous nerve fiber length in diabetic patients.
Yasuda H; Hirai A; Joko M; Terada M; Kawabata T; Maeda K; Haneda M; Kashiwagi A; Maeda T; Kikkawa R
Diabetes Care; 2000 May; 23(5):705. PubMed ID: 10834436
[No Abstract] [Full Text] [Related]
[Next] [New Search]
